Compare Aurora Cannabis Inc (ACB) vs Tempus AI (TEM) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Aurora Cannabis Inc vs Tempus AI — how do they compare? Aurora Cannabis Inc trades at $2.67 (market cap $165.36M), while Tempus AI trades at $56.93 (market cap $10.79B). The key difference: Tempus AI is far larger — about 65.3× Aurora Cannabis Inc's market cap, and Tempus AI is trading nearer its 52-week high, Aurora Cannabis Inc nearer its low. Which is the better fit depends on your goals.
| ACB | TEM | |
|---|---|---|
Market Cap | $165.36M | $10.79B |
Sector | Health | Broad Market / Factor |
52-Week High | $6.23 | $103.25 |
52-Week Low | $2.67 | $42.37 |
Enterprise Value | $99.82M | $11.47B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aurora Cannabis (ACB) trades at $2.71, down 4.58% on the day, with a bearish technical outlook. The company reported a net income of $1.59 million in 2025, a significant improvement from a $69 million loss in 2024, though 2026 guidance projects a net loss of $136 million. Revenue grew to $343.29 million in 2025, but faces headwinds from Canadian reimbursement pressures. Analyst consensus is mixed, with 21.43% buy, 57.14% hold, and 21.43% sell ratings.
The stock's low P/B of 0.47 suggests undervaluation, but negative profitability metrics and a projected reset year in 2027 pose risks. Investment appeal hinges on execution in high-margin international medical markets, though volatility and competitive pressures remain key concerns for shareholders.
Tempus AI (TEM) trades at $60.70, up 0.71% with a bullish technical signal. The stock shows strong analyst support with 8 buy ratings and a $63.50 consensus target, though fundamentals reveal challenges with a -22.2% net margin and -$245M net loss for 2025. Recent FDA approvals and AI platform expansions drive positive sentiment, while cash flow remains dependent on financing activities.
Outlook remains cautiously optimistic given TEM's unique AI healthcare data platform and expanding partnerships, but investors face significant execution risks amid persistent losses. The stock's 7.85 P/S ratio reflects growth expectations, yet profitability concerns and high cash burn require careful monitoring for sustainable turnaround.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Aurora Cannabis Inc
Aurora Cannabis, based in Edmonton, Canada, grows and distributes both medical and recreational cannabis under several brands, including Drift, San Rafael '71, Daily Special, Whistler, Being, and Greybeard. While its main market is Canada, the company has also expanded globally through medical cannabis export agreements.
Read more on ACB →About Tempus AI
Tempus AI Inc is a technology company. It has built the Tempus Platform, which comprises both a technology platform to free healthcare data from silos and an operating system to make the resulting data useful. Its Intelligent Diagnostics use AI, including generative AI, to make laboratory tests more accurate, tailored, and personal.
Read more on TEM →
